Comparative Pharmacology
Head-to-head clinical analysis: ISONIAZID versus MYCOBUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISONIAZID versus MYCOBUTIN.
ISONIAZID vs MYCOBUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits mycolic acid synthesis in Mycobacterium tuberculosis via activation by catalase-peroxidase (KatG) to form reactive species that target InhA, a NADH-dependent enoyl-acyl carrier protein reductase.
Inhibits DNA-dependent RNA polymerase in Mycobacterium tuberculosis, blocking RNA synthesis.
5 mg/kg orally once daily (max 300 mg/day) or 15 mg/kg orally twice weekly (max 900 mg/dose)
300 mg orally once daily, or 300 mg twice weekly for MAC prophylaxis in HIV. For TB, 300 mg daily as part of combination therapy.
None Documented
None Documented
1-4 hours (fast acetylators), 2-5 hours (slow acetylators); prolonged in hepatic impairment.
Clinical Note
moderateIsoniazid + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Isoniazid resulting in a loss in efficacy."
Clinical Note
moderateIsoniazid + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Isoniazid."
Clinical Note
moderateIsoniazid + Ketoconazole
"The serum concentration of Ketoconazole can be decreased when it is combined with Isoniazid."
Clinical Note
moderateTerminal elimination half-life: 35-40 hours (range 30-50 hours). Clinical context: Allows once-daily dosing; prolonged in hepatic or renal impairment.
Renal (75-95% as metabolites and parent drug), fecal (<10%), biliary (minor).
Renal (30% as unchanged drug), fecal (50-60% as metabolites and parent compound), biliary (minor).
Category A/B
Category C
Antimycobacterial
Antimycobacterial
Isoniazid + Itraconazole
"The serum concentration of Itraconazole can be decreased when it is combined with Isoniazid."